Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMISE: Meropenem to Mitigate Sepsis Risk at the Emergency Department
NCT07813767Phase 3Recruiting
- Sponsor
- Hellenic Institute for the Study of Sepsis
- Start
- Oct 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis comparing Placebo with Meropenem (2 arms). Primary endpoint: 28-day mortality. Started Oct 2026; status: recruiting.
02
Drugs
meropenem
03
Conditions
sepsis
Beyond the preview
Go deeper on NCT07813767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07813767.